A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation
Interventions: DRUG: talazoparib
Sponsor: Pfizer
Collaborators: Myriad Genetic Laboratories, Inc.|Medivation, Inc.